Unknown

Dataset Information

0

Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.


ABSTRACT: Triple-negative breast cancers need to be refined in order to identify therapeutic subgroups of patients.We conducted an unsupervised analysis of microarray gene-expression profiles of 107 triple-negative breast cancer patients and undertook robust functional annotation of the molecular entities found by means of numerous approaches including immunohistochemistry and gene-expression signatures. A triple-negative external cohort (n=87) was used for validation.Fuzzy clustering separated triple-negative tumours into three clusters: C1 (22.4%), C2 (44.9%) and C3 (32.7%). C1 patients were older (mean=64.6 years) than C2 (mean=56.8 years; P=0.03) and C3 patients (mean=51.9 years; P=0.0004). Histological grade and Nottingham prognostic index were higher in C2 and C3 than in C1 (P<0.0001 for both comparisons). Significant event-free survival (P=0.03) was found according to cluster membership: patients belonging to C3 had a better outcome than patients in C1 (P=0.01) and C2 (P=0.02). Event-free survival analysis results were confirmed when our cohort was pooled with the external cohort (n=194; P=0.01). Functional annotation showed that 22% of triple-negative patients were not basal-like (C1). C1 was enriched in luminal subtypes and positive androgen receptor (luminal androgen receptor). C2 could be considered as an almost pure basal-like cluster. C3, enriched in basal-like subtypes but to a lesser extent, included 26% of claudin-low subtypes. Dissection of immune response showed that high immune response and low M2-like macrophages were a hallmark of C3, and that these patients had a better event-free survival than C2 patients, characterized by low immune response and high M2-like macrophages: P=0.02 for our cohort, and P=0.03 for pooled cohorts.We identified three subtypes of triple-negative patients: luminal androgen receptor (22%), basal-like with low immune response and high M2-like macrophages (45%), and basal-enriched with high immune response and low M2-like macrophages (33%). We noted out that macrophages and other immune effectors offer a variety of therapeutic targets in breast cancer, and particularly in triple-negative basal-like tumours. Furthermore, we showed that CK5 antibody was better suited than CK5/6 antibody to subtype triple-negative patients.

SUBMITTER: Jezequel P 

PROVIDER: S-EPMC4389408 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.

Jézéquel Pascal P   Loussouarn Delphine D   Guérin-Charbonnel Catherine C   Campion Loïc L   Vanier Antoine A   Gouraud Wilfried W   Lasla Hamza H   Guette Catherine C   Valo Isabelle I   Verrièle Véronique V   Campone Mario M  

Breast cancer research : BCR 20150320


<h4>Introduction</h4>Triple-negative breast cancers need to be refined in order to identify therapeutic subgroups of patients.<h4>Methods</h4>We conducted an unsupervised analysis of microarray gene-expression profiles of 107 triple-negative breast cancer patients and undertook robust functional annotation of the molecular entities found by means of numerous approaches including immunohistochemistry and gene-expression signatures. A triple-negative external cohort (n=87) was used for validation.  ...[more]

Similar Datasets

2015-05-19 | E-GEOD-58812 | biostudies-arrayexpress
2015-05-19 | GSE58812 | GEO
| S-EPMC7285581 | biostudies-literature
2017-08-27 | GSE103091 | GEO
| S-EPMC8740062 | biostudies-literature
2017-06-13 | GSE95700 | GEO
| S-EPMC7543239 | biostudies-literature
| S-EPMC6072816 | biostudies-literature
2021-07-31 | GSE167213 | GEO
| S-EPMC3412597 | biostudies-literature